Allylix Inc. (San Diego, California) has raised $6 million in the first closing of its Series C financing. The company will utilize this sum to commercialize its first three products for the food and fragrance industry, the first of which is nootkatone. The biotechnology firm’s patented metabolic engineering platform, which enables low-cost production of high value terpene products through yeast fermentation, will allow customers to expand the use of nootkatone in existing and new applications. Of this, Allylix CEO Carolyn Fritz said, “The funding validates our technology platform and commercial viability … It gives us the opportunity to deliver high-quality, high-value products to the market.”